Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Amarin's VAZKEPA/VASCEPA failed the primary endpoint of progression-free survival in the Phase 3 EMT2 liver metastasis trial (median PFS 13.5 vs 12.9 months, HR 0.89, p=0.329). However, the key secondary endpoint of overall survival was statistically significantly improved: 5-year OS of 62.0% versus 45.1% with placebo, an approximately 32% reduction in the risk of death (HR 0.68, p=0.030).
Key figures
- Drug Name
- VAZKEPA/VASCEPA (icosapent ethyl)
- Phase Of Trial
- Phase 3
- Os p value
- 0.03
- Pfs p value
- 0.329
- Os 5yr ipe pct
- 62
- Os hazard ratio
- 0.68
- Pfs hazard ratio
- 0.89
- Trial enrollment
- 418
- Os 5yr placebo pct
- 45.1
- Median pfs months ipe
- 13.5
- Os risk reduction pct
- 32
- Median pfs months placebo
- 12.9
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.